American Society of Hirudotherapy

Increased Incidence of Thrombosis in Patients at Risk of Heparin-Induced Thrombocytopenia Receiving Epoprostenol for Cardiac Surgery

Retrospective observational study published in Journal of cardiothoracic and vascular anesthesia (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Observational studyClinical LiteratureBecher EL et al. · Journal of cardiothoracic and vascular anesthesia, 2026

Abstract

OBJECTIVE: Heparin-induced thrombocytopenia (HIT) is a serious concern in cardiac surgery, as heparin use in the at-risk patient can lead to devastating thrombosis. Management strategies for patients with confirmed or suspected HIT include using alternative anticoagulants, such as bivalirudin, but heparin administration in the presence of a potent antiplatelet agent, such as a prostacyclin analogue, has been reported as a safe approach. This retrospective study aimed to evaluate the incidence of thromboembolism in patients with confirmed or suspected HIT who received heparin with intravenous epoprostenol for anticoagulation during cardiac surgery. DESIGN: A single-center retrospective observational study. SETTING: An adult tertiary care referral center. PARTICIPANTS: Sixteen patients who underwent cardiac surgery between 2014 and 2024. All patients had a suspicion of HIT or confirmed HIT by testing. INTERVENTIONS: Patients presenting for cardiac surgery with confirmed or suspected HIT received heparin with intravenous epoprostenol intraoperatively according to an institutional protocol. MEASUREMENTS AND MAIN RESULTS: Collected data included preoperative testing for HIT antibody and serotonin release assay results, as well as whether a thromboembolic event was diagnosed postoperatively. Of the 9 patients who had a positive HIT antibody, 6 had a positive serotonin release assay. Of these 6 patients, 4 had a confirmed thromboembolic event (66.7%). CONCLUSIONS: The rate of thrombosis in our review was considerably higher than the published data on the use of prostacyclin analogues with heparin in patients with HIT, suggesting that this strategy may not be as effective for preventing thrombosis as previously thought. Until larger studies can be conducted, it may be in the best interest of patients with HIT for surgical teams to utilize alternative agents, such as bivalirudin, for anticoagulation in cardiac surgery.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleObservational Study
Indexed MeSH termsHumansHeparinCardiac Surgical ProceduresRetrospective StudiesEpoprostenolFemaleThrombocytopeniaMaleAgedMiddle AgedThrombosisIncidenceAnticoagulantsRisk FactorsPostoperative Complications

Summary

In this single-center retrospective series, 16 cardiac surgery patients with suspected or confirmed heparin-induced thrombocytopenia received heparin plus intravenous epoprostenol; four of six serotonin-release-assay-positive patients suffered thromboembolic events, prompting a call to consider bivalirudin instead.

Why This Matters for Hirudotherapy

This single-center retrospective observational study reviewed 16 cardiac-surgery patients with confirmed or suspected HIT who received heparin together with intravenous epoprostenol (a prostacyclin analogue) per an institutional protocol, and found that 4 of the 6 patients with a positive serotonin release assay (66.7%) had a confirmed postoperative thromboembolic event — a rate the authors note was considerably higher than previously published, leading them to favour alternative agents such as bivalirudin. The relevance to hirudotherapy is contextual: it underscores the unmet need for reliable non-heparin anticoagulation in HIT-prone patients and the move toward direct thrombin inhibitors, the mechanistic family to which the leech secretome's hirudin belongs, rather than evaluating any leech-derived product. As a small retrospective series of 16 patients with very few assay-positive cases, its findings are hypothesis-generating and, by the authors' own statement, await confirmation in larger studies.

Citation

Reference (Vancouver style)

Becher EL, Porter SA, Eaton MP, Chabtini L, Cohen Z. Increased Incidence of Thrombosis in Patients at Risk of Heparin-Induced Thrombocytopenia Receiving Epoprostenol for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2026;40(2):462-466. doi:10.1053/j.jvca.2025.11.016. PMID: 41339211

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.